EBF3 and glioblastoma: All of the EBF3 promoter CpG sites were comparatively highly methylated in five tumour samples, stomach and rectum adenocarcinomas, uterine corpus endometrial carcinoma, urothelial bladder cancer and lung squamous cell carcinoma (Fig. 5a, median = 0.57), but comparatively hypomethylated in four tumour samples, glioblastoma multiforme, lung adenocarcinoma, colon adenocarcinoma and breast invasive carcinoma (median = 0.17).